Christina Konstantaki

Dr. Christina Konstantaki

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 April 2023 in Hellenic Journal of Cardiology
Verified
Journal Article
Open access
DDDimitrios Delialis
Dimitrios Delialis
GGGeorgios Georgiopoulos
Georgios Georgiopoulos
EAEvmorfia Aivalioti
Evmorfia Aivalioti
CKChristina Konstantaki
Christina Konstantaki
EOErmioni Oikonomou
Ermioni Oikonomou
KSKimon Stamatelopoulos
Kimon Stamatelopoulos
Accumulating evidence suggests a substantial contribution of remnant cholesterol (RC) to residual risk for the development or relapse of atherosclerotic cardiovascular disease (ASCVD). We aimed to evaluate the association of RC levels with ASCVD risk by different risk categories and method of RC assessment. We also assessed available evidence on the effect of lipid-lowering therapies (LLTs) on RC levels. English-language searches of Medline, Pubmed and Embase (inception to 31 January 2023); ClinicalTrials.gov (October 2021); and reference lists of studies and reviews. Studies reporting on the risk of the composite endpoint [all-cause mortality, cardiovascular mortality, and major adverse cardiac events (MACE)] by RC levels were included. Moreover, we searched for studies reporting differences in RC levels after administration of LLT(s). Among n=29 studies with 257,387 participants, we found a pooled linear (pooled HR:1.27 per 1-SD increase,95% CI:1.12-1.43,P<0.001,I2=95%,n=15 studies) and non-linear association (pooled HR:1.59 per quartile increase,95% CI:1.35-1.85,P<0.001,I2=87.9%,n=15 studies) of RC levels and the risk of MACE both in patients with and without established ASCVD. Interestingly, the risk of MACE was higher in studies with directly measured vs. calculated RC levels. In a limited number of studies and participants, LLTs reduced RC levels. RC levels are associated with ASCVD risk both in primary and secondary prevention. Directly measured RC levels are associated with ASCVD risk more evidently. Available LLTs tend to decrease RC levels, although the clinical relevance of RC decrease merits further investigation. CRD42022371346.

31 May 2024 in Non-Coding RNA
Verified
Journal Article
Open access
PDF file
MTMaria Tsota
Maria Tsota
TGTota Giardoglou
Tota Giardoglou
ENEvangelia Mentsiou Nikolaou
Evangelia Mentsiou Nikolaou
Panagiotis G. SymianakisPanagiotis G. Symianakis
Panagiotis G. Symianakis
NKNana Kalafati
Nana Kalafati
GDGeorge V. Dedoussis
George V. Dedoussis
Hypertension is a chronic, multifactorial disease, leading to high cardiovascular morbidity and mortality globally. Despite the advantages of pharmaceutical treatments, natural products have gained scientific interest due to their emerging phytotherapeutic properties. Chios mastic is a natural Greek product, consisting of bioactive compounds which modify microRNAs’ (small, expression-regulating molecules) expression. In this study, we investigated the antihypertensive properties of Chios mastic through the assessment of miR-21 levels. Herein, plasma samples of 57 individuals with hypertension, recruited for the purposes of the HYPER-MASTIC study, were analyzed. This was a clinical trial with Chios mastic supplements in which the patients were divided into groups receiving high and low mastic doses and placebo supplements, respectively. miR-21 was significantly upregulated in patients compared to normotensive individuals. Mean changes in miR-21 levels were statistically significant, after adjusting for sex and age, between the placebo and low-dose group and between the low- and high-dose group. Post-intervention miR-21 levels were positively associated with night-time systolic blood pressure, pulse pressure, and central systolic mean arterial pressure and negatively associated with night-time pulse wave velocity in the low-dose group. Our findings suggest a potential implication of miR-21 in the association of Chios mastic with night-time blood pressure measurements.

29 September 2026 in Hellenic Journal of Cardiology
Verified
Journal Article
Open access
DDDimitrios Delialis
Dimitrios Delialis
GGGeorgios Georgiopoulos
Georgios Georgiopoulos
CCChristina Chrysochou
Christina Chrysochou
LSLuke Spray
Luke Spray
SKSimon Kraler
Simon Kraler
KSKimon Stamatelopoulos
Kimon Stamatelopoulos

15 October 2026 in Pharmacology Research & Perspectives
Verified
Journal Article
Open access
PDF file
NKNana Kalafati
Nana Kalafati
AKAnastasia-Areti Kyriazopoulou-Korovesi
Anastasia-Areti Kyriazopoulou-Korovesi
ENEvangelia Mentsiou Nikolaou
Evangelia Mentsiou Nikolaou
MPMaria Papaioannou
Maria Papaioannou
CKChristina Konstantaki
Christina Konstantaki
KSKimon Stamatelopoulos
Kimon Stamatelopoulos
Residual cardiovascular risk persists in patients with adequately controlled hypertension, driven partly by inflammation, oxidative stress and endothelial dysfunction. Chios mastic ( Pistacia lentiscus var. Chia ) has shown antihypertensive, antioxidant and vascular effects in experimental and clinical settings. This trial evaluated whether Chios mastic supplementation confers additional cardiovascular benefits in well‐controlled hypertensive individuals. In this double‐blind, randomized, placebo‐controlled trial, 106 adults with stable, well‐controlled hypertension and variable cardiovascular risk, based on SCORE2, received low‐dose Chios mastic (1500 mg/day), high‐dose Chios mastic (2800 mg/day) or placebo for 3 months. Primary endpoints were changes in 24‐h ambulatory systolic and diastolic blood pressure. Secondary endpoints included vascular function, oxidative stress and proteasome activity in peripheral blood mononuclear cells and red blood cells. Transcriptomic profiling was performed in a predefined high‐risk subgroup. Chios mastic supplementation was well tolerated, with high adherence confirmed by dose‐dependent increases in plasma masticadienonic and isomasticadienonic acids. No significant between‐group differences were observed in 24‐h systolic or diastolic blood pressure after the intervention. Oxidative stress markers and proteasome activity remained unchanged across groups. In high‐risk participants, mastic supplementation induced distinct transcriptomic changes, particularly in pathways related to endothelial junction organization and vascular integrity. Overall, in adults with well‐controlled hypertension and low baseline cardiovascular risk, Chios mastic supplementation did not lower blood pressure over 3 months, likely reflecting a ceiling effect. Transcriptomic findings suggest biologically meaningful vascular effects in individuals with higher residual cardiovascular risk, supporting future investigation in higher‐risk populations.

11 May 2026 in Reports
Verified
Journal Article
Open access
PDF file
LAZAROS YOFOGLULAZAROS YOFOGLU
LAZAROS YOFOGLU
GZGEORGIOS ZERVAS
GEORGIOS ZERVAS
CKChristina Konstantaki
Christina Konstantaki
CΜChrysoula Μoustou
Chrysoula Μoustou
Evaggelia AissopouEvaggelia Aissopou
Evaggelia Aissopou
AAAntonios Argyris
Antonios Argyris
Objectives: The aim of this study was to compare a widely applied table-top digital non-mydriatic camera (Topcon TRC-NW-8) with a handheld digital non-mydriatic camera (Optomed Aurora IQ) regarding the quantitative assessment of the retinal microcirculation using established biomarkers: central retinal arteriolar equivalent (CRAE), central retinal venular equivalent (CRVE) and arterio-venous ratio (AVR). Methods: The present cross-sectional study included 26 randomly selected participants (51 eyes) who underwent retinal imaging of both eyes with the two devices and were analyzed using a static retinal vessel analyzer. Results: The mean differences in CRAE, CRVE and AVR between the two devices (Topcon/Aurora) were 24.96 ± 11.7, 22.7 ± 11.7 and 0.026 ± 0.045, respectively. Strong correlations were observed between devices (r = 0.84 for CRAE, 0.75 for CRVE and 0.83 for AVR; all p < 0.001), with high agreement as indicated by ICC values (0.91, 0.85, and 0.90, respectively). Bland–Altman plots indicated evidence of systemic bias (95% within 2 SD) with no proportional bias, as the differences were consistently distributed across the range of average values. Regression-based equations were derived to approximate the transformation of measurements between devices. Conclusions: The handheld fundus camera demonstrates strong correlation and good relative agreement with the table-top device; however, a consistent device-dependent bias limits the direct interchangeability of absolute measurements. The derived transformation equations may facilitate approximate cross-device comparison, although external validation is required. These findings support the complementary use of handheld devices and highlight the need for calibration strategies when integrating measurements across platforms.